Algernon Pharmaceuticals Stock Performance
| AGNPF Stock | USD 0.06 0 3.16% |
The firm shows a Beta (market volatility) of -0.95, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Algernon Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, Algernon Pharmaceuticals is expected to outperform it slightly. At this point, Algernon Pharmaceuticals has a negative expected return of -0.0617%. Please make sure to confirm Algernon Pharmaceuticals' jensen alpha and the relationship between the potential upside and price action indicator , to decide if Algernon Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Algernon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Algernon Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 2.4 M | |
| Total Cashflows From Investing Activities | -144.6 K |
Algernon |
Algernon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 8.51 in Algernon Pharmaceuticals on August 29, 2024 and sell it today you would lose (2.63) from holding Algernon Pharmaceuticals or give up 30.9% of portfolio value over 90 days. Algernon Pharmaceuticals is currently producing negative expected returns and takes up 10.3511% volatility of returns over 90 trading days. Put another way, 92% of traded otc stocks are less volatile than Algernon, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Algernon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Algernon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Algernon Pharmaceuticals, and traders can use it to determine the average amount a Algernon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.006
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AGNPF |
Estimated Market Risk
| 10.35 actual daily | 92 92% of assets are less volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Algernon Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Algernon Pharmaceuticals by adding Algernon Pharmaceuticals to a well-diversified portfolio.
Algernon Pharmaceuticals Fundamentals Growth
Algernon OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Algernon Pharmaceuticals, and Algernon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Algernon OTC Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 2.41 M | |||
| Price To Book | 1.02 X | |||
| EBITDA | (6.02 M) | |||
| Cash And Equivalents | 872.84 K | |||
| Cash Per Share | 0.44 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (2.91 M) | |||
| Earnings Per Share | (2.28) X | |||
| Total Asset | 8.14 M | |||
About Algernon Pharmaceuticals Performance
By analyzing Algernon Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Algernon Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Algernon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Algernon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada. Algernon Pharmaceuticals is traded on OTC Exchange in the United States.Things to note about Algernon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Algernon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Algernon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Algernon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Algernon Pharmaceuticals has high historical volatility and very poor performance | |
| Algernon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Algernon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (6.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Algernon Pharmaceuticals has accumulated about 872.84 K in cash with (2.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Algernon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Algernon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Algernon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Algernon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Algernon Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Algernon Pharmaceuticals' otc stock. These opinions can provide insight into Algernon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Algernon OTC Stock analysis
When running Algernon Pharmaceuticals' price analysis, check to measure Algernon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Algernon Pharmaceuticals is operating at the current time. Most of Algernon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Algernon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Algernon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Algernon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |